Sep 16, 2026
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study successfully enrolled 100 patients across three U.S. sites, doubling its original target. The company plans to present preliminary data from the study at an upcoming medical conference, with full data expected after all patients complete their 12-month follow-up.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 15, 2026
Pulse Biosciences Finalizes Enrollment for PRECISE-BTN Trial Evaluating nPulse Vybrance System
Pulse Biosciences (NASDAQ:PLSE) has successfully completed patient enrollment for its PRECISE-BTN clinical trial, which evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study expanded from 50 to 100 patients, with enrollment occurring at three U.S. clinical sites. The first patient has also completed their 12-month follow-up, and the trial will assess safety, nodule volume reduction, symptom relief, hormone normalization, and quality of life improvements.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Somewhat-Bullish